Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis

Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy

(2012) Alice Y. Ho et al.   CANCER

Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?

(2011) C. M. Kelly et al.   ANNALS OF ONCOLOGY

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes

(2011) G. Cancello et al.   BREAST CANCER RESEARCH AND TREATMENT

St. Gallen 2011: Summary of the Consensus Discussion

(2011) Michael Gnant et al.   Breast Care

Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer

(2011) Lorenzo Livi et al.   CANCER

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer

(2011) Heather L. McArthur et al.   CANCER

Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype

(2011) Rachel L. Theriault et al.   Clinical Breast Cancer

High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers

(2011) Akiyo Horio et al.   International Journal of Clinical Oncology

Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metastatic Potential of T1 Breast Cancer can be Predicted by the 70-gene MammaPrint Signature

(2010) Stella Mook et al.   ANNALS OF SURGICAL ONCOLOGY

Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less

(2010) Ji Hyun Kwon et al.   BMC CANCER

Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller

(2010) H.W. Lai et al.   EJSO

Trastuzumab Treatment in T1ab, Node-Negative, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Carcinomas

(2010) Manuel Jorge Rodrigues et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of small HER2-positive breast cancers

(2010) Susana Banerjee et al.   LANCET ONCOLOGY

Tumor size and survival in breast cancer—a reappraisal

(2010) William D. Foulkes et al.   Nature Reviews Clinical Oncology

Prognosis and Outcome of Small (

(2010) S. Amar et al.   ONCOLOGIST

Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy

(2009) I. Garassino et al.   BREAST

A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?

(2009) Yeon Hee Park et al.   BREAST CANCER RESEARCH AND TREATMENT

T1N0 Triple Negative Breast Cancer: Risk of Recurrence and Adjuvant Chemotherapy

(2009) Henry G. Kaplan et al.   Breast Journal

Clinical Relevance ofHER2Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer

(2009) Giuseppe Curigliano et al.   JOURNAL OF CLINICAL ONCOLOGY

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

(2009) Ana M. Gonzalez-Angulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Early breast cancer

(2009) John R Benson et al.   LANCET